Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Profile: ImmunoCellular Therapeutics Ltd.

Yu JS.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1745. doi: 10.4161/hv.23357. No abstract available.

PMID:
23817320
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Ovarian cancer vaccine candidate DPX-Survivac: positive interim results from phase 1.

Riedmann EM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1743. No abstract available.

PMID:
23980265
[PubMed - indexed for MEDLINE]
3.

Immunotherapy for ovarian cancer: what's next?

Kandalaft LE, Powell DJ Jr, Singh N, Coukos G.

J Clin Oncol. 2011 Mar 1;29(7):925-33. doi: 10.1200/JCO.2009.27.2369. Epub 2010 Nov 15. Review.

PMID:
21079136
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Dendritic cell vaccines to combat glioblastoma.

Wheeler CJ.

Expert Rev Neurother. 2010 Apr;10(4):483-6. doi: 10.1586/ern.10.26. No abstract available.

PMID:
20367199
[PubMed - indexed for MEDLINE]
5.

Vaccine-based clinical trials in ovarian cancer.

Leffers N, Daemen T, Boezen HM, Melief KJ, Nijman HW.

Expert Rev Vaccines. 2011 Jun;10(6):775-84. doi: 10.1586/erv.11.42. Review.

PMID:
21692699
[PubMed - indexed for MEDLINE]
6.

The contenders. Vaccines and viruses take aim at cancer cells.

Clancy F.

Minn Med. 2005 Apr;88(4):24-8. No abstract available.

PMID:
15940888
[PubMed - indexed for MEDLINE]
7.

Immune therapy for ovarian cancer: promise and pitfalls.

Thibodeaux SR, Curiel TJ.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):102-19. doi: 10.3109/08830185.2011.567361. Review.

PMID:
21557637
[PubMed - indexed for MEDLINE]
8.

Dendritic cells and interleukin 12 as adjuvants for tumor-specific vaccines.

Grohmann U, Bianchi R, Belladonna ML, Silla S, Surace D, Fioretti MC, Puccetti P.

Adv Exp Med Biol. 1997;417:579-82. No abstract available.

PMID:
9286421
[PubMed - indexed for MEDLINE]
9.

Immunotherapy in human glioblastoma.

Szabo AT, Carpentier AF.

Rev Neurol (Paris). 2011 Oct;167(10):668-72. doi: 10.1016/j.neurol.2011.07.002. Epub 2011 Aug 31. Review.

PMID:
21885075
[PubMed - indexed for MEDLINE]
10.

Cancer stem cell immunotherapy: the right bullet for the right target.

Ghebeh H, Bakr MM, Dermime S.

Hematol Oncol Stem Cell Ther. 2008 Jan-Mar;1(1):1-2. No abstract available.

PMID:
20063521
[PubMed - indexed for MEDLINE]
11.

Current approaches in ovarian cancer vaccines.

Reinartz S, Wagner U.

Minerva Ginecol. 2004 Dec;56(6):515-27. Review.

PMID:
15729204
[PubMed - indexed for MEDLINE]
12.

Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.

Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):71-86. doi: 10.3109/08830185.2011.561507. Review.

PMID:
21557635
[PubMed - indexed for MEDLINE]
13.

Two years of Provenge.

Riedmann EM.

Hum Vaccin Immunother. 2012 Apr;8(4):505. doi: 10.4161/hv.20489. No abstract available.

PMID:
22832253
[PubMed - indexed for MEDLINE]
Free Article
14.

Interleukin-12 as an adjuvant for cancer immunotherapy.

Rodolfo M, Colombo MP.

Methods. 1999 Sep;19(1):114-20. Review.

PMID:
10525447
[PubMed - indexed for MEDLINE]
15.

Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?

Chiriva-Internati M, Cobos E, Cannon MJ.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):67-70. doi: 10.3109/08830185.2011.571731.

PMID:
21557634
[PubMed - indexed for MEDLINE]
16.

Profile: association for cancer immunotherapy (CIMT).

Huber C.

Hum Vaccin Immunother. 2012 May;8(5):546. doi: 10.4161/hv.20895. Epub 2012 May 1. No abstract available.

PMID:
22647579
[PubMed - indexed for MEDLINE]
Free Article
17.

Immunotherapy trials for glioblastoma multiforme: promise and pitfalls.

Yong RL, Lonser RR.

World Neurosurg. 2012 May-Jun;77(5-6):636-8. doi: 10.1016/j.wneu.2011.10.010. Epub 2011 Nov 1. No abstract available.

PMID:
22120230
[PubMed - indexed for MEDLINE]
18.

CDX-1401 combined with TLR agonist: positive phase 1 results.

Riedmann EM.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1742. No abstract available.

PMID:
23980263
[PubMed - indexed for MEDLINE]
19.

Heat shock protein-peptide complex in the treatment of glioblastoma.

See AP, Pradilla G, Yang I, Han S, Parsa AT, Lim M.

Expert Rev Vaccines. 2011 Jun;10(6):721-31. doi: 10.1586/erv.11.49. Review.

PMID:
21692695
[PubMed - indexed for MEDLINE]
20.

Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.

Chiang CL, Kandalaft LE, Coukos G.

Int Rev Immunol. 2011 Apr-Jun;30(2-3):150-82. doi: 10.3109/08830185.2011.572210. Review.

PMID:
21557641
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk